benzoyl peroxide; tretinoin - Profile

What are the generic drug sources for benzoyl peroxide; tretinoin and what is the scope of freedom to operate?

Benzoyl peroxide; tretinoin is the generic ingredient in one branded drug marketed by Mayne Pharma and is included in one NDA. There are thirteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Benzoyl peroxide; tretinoin has one hundred and seven patent family members in eighteen countries.

Summary for benzoyl peroxide; tretinoin

International Patents:	107
US Patents:	13
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for benzoyl peroxide; tretinoin

Constraining patent/regulatory exclusivity:

11,071,878

Dosage:

CREAM;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for benzoyl peroxide; tretinoin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mayne Pharma	TWYNEO	benzoyl peroxide; tretinoin	CREAM;TOPICAL	214902-001	Jul 26, 2021		RX	Yes	Yes	12,295,935
Mayne Pharma	TWYNEO	benzoyl peroxide; tretinoin	CREAM;TOPICAL	214902-001	Jul 26, 2021		RX	Yes	Yes	12,357,602		Y
Mayne Pharma	TWYNEO	benzoyl peroxide; tretinoin	CREAM;TOPICAL	214902-001	Jul 26, 2021		RX	Yes	Yes	12,257,348		Y
Mayne Pharma	TWYNEO	benzoyl peroxide; tretinoin	CREAM;TOPICAL	214902-001	Jul 26, 2021		RX	Yes	Yes	12,491,163		Y

International Patents for benzoyl peroxide; tretinoin

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2020170032
Brazil	PI0808160	PROCESSO PARA REVESTIR UM MATERIAL PARTICULADO SÓLIDO, INSOLÚVEL EM ÁGUA, COM UM ÓXIDO DE METAL, MATERIAL PARTICULADO REVESTIDO, PARTÍCULAS, MÉTODOS PARA TRATAR UMA CONDIÇÃO DE SUPERFÍCIE EM UM INDIVÍDUO, E PARA PREVENIR, REDUZIR, OU ELIMINAR PRAGAS EM UM LOCAL, E, USO DE MATERIAL PARTICULADO REVESTIDO
Canada	2773544	MICROCAPSULES A NOYAU STABILISE, PROCEDE DE LEUR PREPARATION ET UTILISATIONS DE CELLES-CI (CORE STABILIZED MICROCAPSULES, METHOD OF THEIR PREPARATION AND USES THEREOF)
China	101277757	Metal oxide coating of water insoluble ingredients

Supplementary Protection Certificates for benzoyl peroxide; tretinoin

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0526708	C300097	Netherlands		PRODUCT NAME: BOSENTAN, DESGEWENST IN DE VORM VAN EEN ZOUT OF EEN HYDRAAT OF IN DE VORM VAN EEN ESTER VAN DE HYDROXYLGROEP VAN DE 2-HYDROXYETHOXY REST MET EEN ZUUR MET DE FORMULE R5-OH, WAARIN R5 EEN C1-7-ALKANOYL, BENZOYL, OF HETEROCYCLYCARBONYL VOORSTELT; NATL. REGISTRATION NO/DATE: U/1/02/220/001 - 005 20020515; FIRST REGISTRATION: CH IKS 58841 01 - 02 20020228
1458369	122008000041	Germany		PRODUCT NAME: ADAPALEN IN KOMBINATION MIT BENZOYLPEROXID; NAT. REGISTRATION NO/DATE: 67913.00.00 20080229; FIRST REGISTRATION: DAENEMARK 40440 20071218
1586316	SPC/GB11/054	United Kingdom		PRODUCT NAME: BROMFENAC 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID OR A PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REGISTERED: UK EU/1/11/692/001 20110523
0591275	SPC/GB05/030	United Kingdom		PRODUCT NAME: NITISINONE (2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/303/001 20050221; UK EU/1/04/303/002 20050221; UK EU/1/04/303/003 20050221

Investment Scenario, Market Dynamics, and Financial Trajectory for Benzoyl Peroxide and Tretinoin

Last updated: February 3, 2026

Summary

Benzoyl peroxide and tretinoin are foundational dermatological agents with established markets primarily focused on acne treatment. Their combined market value, driven by aging population, rising acne prevalence, and expanding indications, presents lucrative investment opportunities. Current market trends favor innovation in formulation and therapeutic breadth, influencing growth trajectories. This analysis evaluates market size, competitive landscape, regulatory environment, and future revenue potential to inform strategic investment decisions.

---

1. Market Overview of Benzoyl Peroxide and Tretinoin

Parameter	Benzoyl Peroxide	Tretinoin
Primary Indication	Acne vulgaris	Acne, photoaging, skin rejuvenation
Global Market Value (2022)	~$540 million	~$1.2 billion
Projected CAGR (2023-2028)	4.5%	6.2%
Key Producers	Galderma, Johnson & Johnson, Teva	Bayer, Almirall, Galderma

Market Drivers

• Rising prevalence of acne across all age groups, especially adolescents and young adults.
• Growing demand for topical therapies with minimal systemic effects.
• Expansion of indications into anti-aging and skin rejuvenation.
• Increased adoption of combination therapies.

Market Constraints

• Over-the-counter (OTC) availability reduces prescription-driven revenue.
• Skin irritation and other side effects impact patient adherence.
• Competitive generic landscape.

---

2. Market Dynamics and Drivers

2.1. Demographic and Epidemiological Trends

Factor	Impact	Details
Age Groups	Increased market	Adolescents and adults with acne and aging skin.
Gender	Slight male dominance	Acne affects both genders; women increasingly using tretinoin for anti-aging.
Geographical Distribution	Growing markets in Asia-Pacific and Latin America	Due to rising disposable income and skincare awareness.

2.2. Regulatory Environment

Region	Status	Implications
US	OTC and prescription pathways	OTC for benzoyl peroxide; prescription for tretinoin.
Europe	Prescription-only	Increasing scrutiny over safety and side effects.
Emerging Markets (Asia, Africa)	Growing OTC availability	Market penetration increasing, but regulatory hurdles persist.

2.3. Innovation and Development Trends

Trend	Implication
Formulation Innovation	New gel, foam, and microencapsulation delivery systems improve tolerance and efficacy.
Combination Products	Fixed-dose combinations like benzoyl peroxide with clindamycin or adapalene with tretinoin.
Expanded Indications	Anti-aging, keratosis pilaris, melasma.

---

3. Financial Trajectory and Investment Opportunities

3.1. Revenue Projection (2023-2028)

Parameter	Benzoyl Peroxide	Tretinoin
Current Market Size (2022)	~$540 million	~$1.2 billion
Expected CAGR	4.5%	6.2%
Estimated 2028 Market Size	~$756 million	~$1.69 billion

3.2. Key Drivers of Revenue Growth

• Patent expirations leading to increased generic penetration but opportunities in formulation improvements.
• Expanding indications, especially in anti-aging skin care.
• Launch of combination therapies and innovative formulations.

3.3. Investment Risks

• Regulatory changes restricting OTC availability.
• High competitive pressure with numerous generics.
• Side effects limiting patient adherence.
• Market saturation in mature regions.

---

4. Competitive Landscape Comparison

Company	Patent Status	Market Share	Strategic Focus	Innovations
Galderma	Patent expirations underway	Leading	Formulation innovation & anti-aging	Microencapsulated tretinoin products
Bayer	Generic manufacturer	Moderate	Combination therapies	Fixed-dose formulations
Johnson & Johnson	OTC benzoyl peroxide	High	Consumer skin care	Novel delivery systems

Recent M&A and Licensing Activity (2020-2023)

• Acquisition of dermatology portfolios by private equity firms.
• Licensing deals focusing on combination products and formulations.
• Pipeline development targeting anti-aging trends.

---

5. Policy and Reimbursement Landscape

Region	Reimbursement Status	Impact
US	Variable; primarily private insurers	OTC benzoyl peroxide often not reimbursed; prescription tretinoin may be covered.
Europe	Mostly reimbursed	Reimbursement policies favor prescribed tretinoin.
Emerging Markets	Limited or no coverage	Out-of-pocket spending dominates, influencing sales volume.

Implication for Investors

• Rx-driven revenues are susceptible to reimbursement policies.
• OTC formulations offer scale but lower margins.

---

6. Comparative Analysis: Benzoyl Peroxide vs. Tretinoin

Aspect	Benzoyl Peroxide	Tretinoin
Mechanism	Antibacterial, keratolytic	Retinoid, promotes cell turnover
Administration	OTC, prescription	Prescription for most uses, OTC for some formulations
Market Growth Rate	4.5% CAGR	6.2% CAGR
Indications	Acne vulgaris	Acne, photoaging, hyperkeratosis
Patent Status	Mostly expired	Patent expirations ongoing / patent protected formulations exist
Market Size (2022)	~$540 million	~$1.2 billion

---

7. Future Outlook and Strategic Investment Insights

• Emerging innovations in nano-encapsulation and sustained-release formulations can enhance tolerability, expanding patient adherence.
• Precision medicine approaches may allow targeted therapy, increasing market share.
• Pipeline expansion into anti-aging segments suggests multi-indication growth potential.
• Regional growth driven by emerging markets; strategic expansion in Asia and Latin America is recommended.
• Potential Licensing and M&A activity will influence market consolidation and competitive positioning.

---

8. Key Takeaways

• The dermatology segment for benzoyl peroxide and tretinoin remains robust, bolstered by demographic and technological trends.
• Tretinoin shows higher CAGR due to expanding indications and anti-aging applications, promising more aggressive growth.
• Patent expirations create opportunities for generics, but innovation in formulations and combination products offers premium revenue streams.
• Investment should consider regulatory landscapes, reimbursement policies, and regional market maturity.
• Strategic partnerships and M&A can enhance market penetration and product portfolios, especially in emerging markets.

---

9. Frequently Asked Questions (FAQs)

Q1: What factors most significantly influence the growth of benzoyl peroxide and tretinoin markets?
A: Demographic trends (adolescent and adult acne), innovation in formulations, expanding indications (including anti-aging), and regional market penetration primarily drive growth.

Q2: How do patent expirations impact the profitability of these drugs?
A: Patent expirations lead to generic entry, reducing prices and margins. However, innovation in delivery and combination therapies can sustain profitability.

Q3: Are there regulatory risks for these compounds?
A: Yes. Regulatory agencies may restrict OTC availability or impose safety mandates, affecting sales channels and revenue models.

Q4: Which regions represent the most promising markets for future growth?
A: Asia-Pacific and Latin America are high-growth regions due to rising disposable income, increasing skin-conscious consumer behavior, and regulatory reforms.

Q5: How do emerging combination products influence market dynamics?
A: They can capture higher market shares through improved efficacy, better compliance, and expanded indications, creating new revenue streams.

---

References:

[1] MarketsandMarkets. "Dermatology Drugs Market." 2022.
[2] Grand View Research. "Acne Medication Market Analysis." 2022.
[3] U.S. FDA. "Guidance on Topical Retinoids." 2021.
[4] Deloitte Insights. "Pharmaceutical Patent Trends." 2022.
[5] IQVIA. "Global Dermatology Market Data." 2022.

---

End of Document